Longevity medicine is a field in the process of inventing itself — assembling, from the raw material of geroscience, a clinical practice that has outpaced both its evidence base and its regulatory framework. Growth hormone secretagogues sit at the center of this process: compounds with genuine pharmacological activity, plausible mechanistic rationales, preclinical evidence that the longevity community cites extensively, and a human clinical evidence base that remains thin at the doses and durations used in optimization practice. Understanding what they do — and what remains genuinely unknown — requires separating the mechanistic hypothesis from the clinical demonstration, a distinction that the optimization market has incentives to obscure.
The Secretagogue Class
Growth hormone secretagogues work through two principal receptor pathways. GHRH analogues — including sermorelin (a truncated GHRH peptide) and the modified CJC-1295 — stimulate the pituitary somatotropes to release growth hormone by mimicking the native hypothalamic signal. GHRPs (growth hormone releasing peptides) — ipamorelin, hexarelin, GHRP-2, GHRP-6 — stimulate GH release through the ghrelin receptor (GHS-R), a pathway that is distinct from and largely additive to the GHRH axis. Research has established that combining a GHRH analogue with a GHRP produces synergistic GH release that exceeds either agent alone — which is why the ipamorelin/CJC-1295 combination protocol has become a standard optimization prescription. The pharmacological rationale is legitimate. The clinical extrapolation from GH pulse stimulation to meaningful tissue-level benefit at the doses achievable with secretagogues is considerably less certain.
The physiological case for GH optimization in middle-aged adults rests on the well-documented phenomenon of somatopause: the age-related decline in GH pulsatility and IGF-1 levels that begins in the third decade and continues at approximately fifteen percent per decade thereafter. This decline is associated, in cross-sectional data, with unfavorable changes in body composition, bone density, muscle mass, and metabolic parameters. The question that the optimization market has answered affirmatively — that reversing somatopause through secretagogue administration produces clinically meaningful improvements in these parameters — is more nuanced than that answer implies. The associations between GH decline and body composition changes are not uniformly causal; aging involves multiple simultaneous biological processes, and isolating the contribution of GH decline from those of sex hormone changes, reduced physical activity, and altered nutritional patterns requires the kind of controlled experimental design that has not been applied to secretagogue interventions at scale.
What the Human Evidence Actually Shows
The human clinical evidence for growth hormone secretagogues in healthy aging adults is limited and mostly dated. Sermorelin received FDA approval in 1997 for pediatric growth hormone deficiency and was studied in adult GH deficiency populations in the late 1990s, but the adult indication was ultimately not pursued commercially and the compound’s patent life has expired. Clinical trials of secretagogues in healthy older adults are sparse, small, and of limited duration — none approaching the multi-year treatment periods that characterize real-world optimization protocols. Tesamorelin, a GHRH analogue, has the most robust human evidence base, derived from its FDA-approved indication for HIV-associated lipodystrophy; the cardiovascular and body composition benefits documented in that population are real, but extrapolation to healthy aging individuals without that specific metabolic phenotype requires assumptions that the evidence does not fully support.
The IGF-1 Safety Concern
The safety question that hangs over GH secretagogue optimization is the relationship between chronically elevated IGF-1 — the downstream mediator of most GH’s anabolic effects — and cancer risk. Epidemiological evidence has consistently found associations between high IGF-1 levels and increased risk of several cancers, including prostate, breast, and colorectal cancer. The direction of causality in observational data is difficult to establish, and the mechanistic link between IGF-1 and malignancy — through cell proliferation pathways that are evolutionarily conserved — is biologically plausible. The optimization protocols used in clinical practice aim to restore IGF-1 to youthful physiological ranges rather than to supraphysiologic levels, which proponents argue limits cancer risk; the evidence that optimization-range IGF-1 elevation carries the same risk profile as pathologically elevated levels is simply not available.
The Regulatory and Clinical Governance Gap
The governance gap surrounding growth hormone secretagogue use reflects a broader failure of the regulatory and medical credentialing systems to keep pace with the innovation of clinical practice in the longevity space. Physicians who prescribe secretagogues through compounding pharmacies are practicing within their license — the compounds are pharmaceutical-grade, the prescriptions are legal, and the patient relationships are real. The question of whether the prescribing is evidence-based, in any defensible clinical sense, is a different question that the licensing and credentialing system is not designed to adjudicate. The patient who receives a secretagogue protocol from a board-certified physician at a longevity clinic has no reliable mechanism for distinguishing between a practitioner whose prescribing reflects a sophisticated interpretation of a genuinely limited evidence base and one whose prescribing reflects a business model organized around patient demand rather than clinical judgment. That indistinguishability is the central governance problem of optimization medicine — and it is not going to be resolved by the regulatory tools currently available.
